Moors & Cabot’s Johnson & Johnson JNJ Stock Holding History

Moors & Cabot’s Portfolio JNJ Stock Details JNJ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,000	Closed	-$17K	–	533
2016 Q1	$17K	Hold	1,000	–	–	﹤0.01%	508
2015 Q4	$13K	Hold	1,000	–	–	﹤0.01%	503
2015 Q3	$1K	Hold	1,000	–	–	﹤0.01%	505
2015 Q2	$3K	Hold	1,000	–	–	﹤0.01%	524
2015 Q1	$5K	Buy	+1,000	New	+$102K	﹤0.01%	512

Other funds holding JNJ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Moors & Cabot's JNJ Position: Q1 2026 in Review

Moors & Cabot reduced its Johnson & Johnson (JNJ) stake by 1.2% in Q1 2026, selling an estimated $351K and leaving 120,078 shares worth $29.4M. The position accounts for 1.26% of the portfolio, ranked #11.

Moors & Cabot first reported a position in JNJ in Q1 2014 and has held it in 49 quarters since. 4,616 funds tracked by Wall St. Rank hold JNJ as of Q1 2026.

Moors & Cabot held 120,078 shares of Johnson & Johnson worth $29.4M as of Q1 2026.
Moors & Cabot sold 1,508 Johnson & Johnson shares in Q1 2026, an estimated $351K.
Johnson & Johnson made up 1.26% of Moors & Cabot's portfolio in Q1 2026, its #11 holding.
Moors & Cabot first reported a position in Johnson & Johnson in Q1 2014 and has held it in 49 quarters since.
4,616 funds tracked by Wall St. Rank held Johnson & Johnson as of Q1 2026.

Based on Moors & Cabot's 13F filing for Q1 2026, filed 8 May 2026.